-
Drug-Eluting Beads Bronchial Arterial Chemoembolization Combined with Immunotherapy Resulted in Pathological Complete Response of Squamous Cell Lung Cancer: A Case Report
18 Dec 2024 16:06 GMT
… doxorubicin, pirarubicin, irinotecan, oxaliplatin, cisplatin, gemcitabine, etc … drug for treating lung cancer. Importantly, epirubicin … arterial chemoembolization in lung cancer patients with hemoptysis … pathologic assessment of lung cancer resection specimens …
-
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
07 Feb 2024 12:27 GMT
… cancers to date, including lung cancer, bladder cancer, esophageal … response (MPR).
About Lung Cancer
Lung cancer is the leading … with a fluoropyrimidine, oxaliplatin, and irinotecan. This … lung cancer; Checkmate 816-neoadjuvant non-small cell lung cancer, …
-
Biomarker-Guided Treatment Approaches Transform Lung and GI Cancer Management
13 Dec 2024 20:00 GMT
… (CRC), non–small cell lung cancer (NSCLC), and gastric cancer … know about from melanoma, lung cancer, and cholangiocarcinoma, exist in … to capecitabine [Xeloda] and oxaliplatin [CAPOX] compared with … the GI and Lung Cancer Biomarker Consortiums, click here …
-
The Relationship Between the Expression of circFAT1 and Immune Cell in Patients with Non-Small Cell Lung Cancer
31 Oct 2023 03:22 GMT
… small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases. … in non-small cell lung cancer: gene regulation, impact … in non-small cell lung cancer: mechanistic insights and therapeutic … (SKA1) axis regulates oxaliplatin resistance in breast cancer …
-
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Provides Benefits for Patients with Resectable Non-Small Cell Lung Cancer Across PD-L1 Expression Levels with Three-Year Follow Up in CheckMate -816 Trial
17 Oct 2023 20:05 GMT
… tumor types, including lung cancer, bladder cancer, esophageal … distant metastases.
About Lung Cancer
Lung cancer is the leading … with a fluoropyrimidine, oxaliplatin, and irinotecan. This … lung cancer; Checkmate 816–neoadjuvant non-small cell lung cancer, …
-
Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -77T Trial
17 Oct 2023 19:36 GMT
… of four tumor types: lung cancer, bladder cancer, esophageal … response (MPR).
About Lung Cancer
Lung cancer is the leading cause … with a fluoropyrimidine, oxaliplatin, and irinotecan. This … lung cancer; Checkmate 816–neoadjuvant non-small cell lung cancer, …
-
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
22 Sep 2023 11:10 GMT
… of four tumor types: lung cancer, bladder cancer, esophageal … response (MPR).
About Lung Cancer
Lung cancer is the leading cause … with a fluoropyrimidine, oxaliplatin, and irinotecan. This … lung cancer; Checkmate 816–neoadjuvant non-small cell lung cancer, …
-
Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
11 Sep 2023 11:28 GMT
… L1 ≥1%.
About Lung Cancer
Lung cancer is the leading cause … positive) non-small cell lung cancer (NSCLC).
OPDIVO® (nivolumab … with a fluoropyrimidine, oxaliplatin, and irinotecan. This … lung cancer; Checkmate 816–neoadjuvant non-small cell lung cancer, …
-
Pseudoprogression Disease in a Patient with Small Cell Lung Cancer on Immune Checkpoint Inhibitor Therapy
31 Aug 2023 19:49 GMT
… Etoposide 100mg and Oxaliplatin 10mg, but on … biopsy of left lung tumor. Pathological Result: … Small Cell Lung Cancer
Small cell lung cancer’s rapid … lung cancer, particularly in small-cell lung cancer patients.
The role of immunotherapy in lung cancer …
-
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Lung Cancer: Current Perspectives
03 Jul 2023 07:52 GMT
… are commonly expressed on lung cancers, namely PD-L1 … demonstrated that conditioning with oxaliplatin resulted in macrophage activation … Given the heterogeneity of lung tumors described above, it … as tumor marker in lung cancer. Lung Cancer. 2012;76(2):138– …
About
© 1995-2024